Camurus announces publication of Phase 3 study results showing long-term safety, efficacy and high rates of patient satisfaction with Buvidal®
Individualized treatment of opioid dependence with weekly and monthly Buvidal® was well-tolerated and effective, with a high (73.6%) patient retention across the 48-week study 83.4% of participants transferred from daily sublingual buprenorphine responded that Buvidal® was better than their previous treatment Lund, Sweden — 4 June 2019 — Camurus announces that the leading drug dependence journal Addiction has today published full results from a 48-week, open-label, global Phase 3 study of weekly and monthly Buvidal® (prolonged-release buprenorphine), the first and only long-acting